Successes and Challenges of NK Immunotherapy

Breaking Tolerance to Cancer Resistance
Herausgeber: Bonavida, Benjamin; Jewett, Anahid

• Gebundenes Buch

Produktbeschreibung

Successes and Challenges of NK Immunotherapy: Increasing Anti-tumor Efficacy describes the unique therapeutic applications of NK cells to fight cancers and eliminate the bulk and subset of cancer stem cells responsible for metastasis, relapse and recurrences. The book provides information on the development, engineering, mechanisms of action, response to various preclinical models, and applications in various clinical trials. Sections cover the development of highly engineered cytotoxic NK cells, their mechanisms of action, preclinical and clinical applications, the development and application of CAR-NK cells, and new NK-drug conjugates, also emphasizing that activated NK cells can target and kill highly resistant cancer stem cells. Written by the leading experts on NK immunotherapy worldwide, this is a valuable resource for researchers, clinicians and members of the biomedical field who are interested in understanding novel and efficient therapies to fight cancers.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Elsevier Science
• Seitenzahl: 538
• Erscheinungstermin: 25. Juni 2021
• Englisch
• Gewicht: 1270g
• ISBN-13: 9780128243756
• ISBN-10: 0128243759
• Artikelnr.: 60007053

Inhaltsangabe

Section 1: Modulation of NK Antitumor Activities1. Engineered Human
Pluripotent Stem Cell-Derived NK Cells with Improved Anti-tumor Activity2.
The Cancer - NK cell Immunity Cycle3. Immunometabolic reprogramming of NK
cells for immunotherapy of solid tumors4. Immunoregulation of NK cells:
Similarities and Differences Compared to T cells5. Tracking the decay of
TGFb-resistant NK cells identifies an immune clock of innate cell aging
Section 2: Regulation of NK Antitumor Activities6. Oncolytic virus therapy
for cancer; role in activation of NK cells7. Rendering NK cells resistant
to immune suppression: genetic modification with a dominant negative
receptor for TGF-Beta8. Cystatin F, an inhibitor of cysteine cathepsins,
regulates the cytotoxicity of NK cells9. The NCR2-PCNA Immune Checkpoint
and Natural Killer-based immunotherapy10. Tumor derived soluble human NKG2D
ligand mediated perturbations in NK cell metabolism and therapeutic
implications11. The expression of high affinity recombinant Fc receptors by
engineered natural killer cells to enhance cancer cell killing by ADCC
Section 3: NK Antitumor Immunotherapy12. The many key functions of Natural
Killers cells in premalignant and malignant stages of tumorigenesis; when
these gatekeepers are gone or defective anarchy ensues13. Phenotypic
plasticity: the emergence of cancer stem cells and collective cell
migration14. Stem cell-engineered invariant natural killer T cells for
cancer immunotherapy15. Natural killer cells in the glioblastoma stem cell
niche microenvironment16. CAR-redirected Cytokine-Induced Killer
lymphocytes against sarcomas17. The Effect of Natural Killer Cells on HIV-1
Rebound in Humanized Mice
Section 4: NK Antitumor Immunotherapy 218. NK cells are innate actors in
the immunosurveillance of melanoma19. Patients with prostate cancer
associate with altered features of Natural Killer cells in terms of
pro-angiogenic function and M2-like macrophage polarization capacity20. New
therapeutic approaches to target malignant gliomas21. Mobilizing Human iNKT
cells for Cancer Immunotherapies22. Initial Innate Immune Responses to
Tumor Metastasis23. Regulating NK cell homeostasis and function by tumor
associated NKG2D ligand MIC24. Natural Killer Cells in Cancer Immunotherapy
and Oncolytic Virotherapy
Section 5: General Concluding Remarks and Future Perspectives